The distinguished translational oncology researchers on Unum’s Scientific Advisory Board (SAB) provide counsel to support continued development of our ACTR platform, and provide us with key insights as we develop our broader research agenda. Comprised of pioneers in immuno-oncology, our SAB includes:
Dario Campana, MD, PhD
Dr. Campana, Unum’s scientific founder and inventor of the ACTR technology, serves as the advisory board’s chair. Dario is a pioneer in the field of cancer cell therapies and has dedicated his career to translational oncology research. He currently serves as Professor, Department of Pediatrics and holds the Mrs. Lee Kong Chian Chair in Advanced Cellular Therapy at the National University of Singapore. In his prior role as Member and Vice Chair for Laboratory Research in the Department of Oncology at St. Jude Children’s Research Hospital, he created the CD19-41BB-CD3zeta chimeric antigen receptor that was subsequently shown to be highly effective in treating patients with acute lymphoblastic leukemia.
Malcolm Brenner, MD, PhD
Dr. Brenner’s career has focused on gene therapy and cancer-related immunotherapies, including genetic-modification of T-cells. He is currently the founding director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital. In his prior work at St. Jude Children's Research Hospital, he conducted one of the first human gene therapy studies, using a retroviral vector to transduce bone marrow stem cells. He has also served as President of the International Society for Cellular Therapy; President of the American Society of Gene Therapy; and Editor-in-Chief of the journal Molecular Therapy.
John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Dr. Gribben currently serves as Professor of Medical Oncology; Director of the Centre of Hemato-Oncology; and Director of Stem Cell Transplantation at Saint Bartholomew's Hospital, Queen Mary, University of London School of Medicine. An internationally recognized translational researcher, his primary research interests include cancer immunotherapies and new treatments for B-cell malignancies. His laboratory focuses on the role of the tumor microenvironment as a target for new therapeutic approaches.
Crystal L. Mackall, MD
Dr. Mackall is currently Professor of Pediatrics and of Medicine at the Stanford University School of Medicine. She additionally serves as associate director of the Stanford Cancer Institute, co-medical director of the Stanford Laboratory for Cell and Gene Medicine, and as program leader in pediatric cancer immunotherapy. Much of her career was spent at the National Cancer Institute, where she served as Head of Immunology Section and Chief of the Pediatric Oncology Branch. Her work focuses on translational research and immunotherapy for childhood cancers. An expert in the field of T-cell homeostasis, Dr. Mackall has experience leading clinical trials of engineered T-cell and Natural Killer cell therapies. She also co-leads the StandUp2Cancer/St.Baldrick’s/NCI Pediatric Dream Team.